Exelixis Inc. (EXEL)
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
Here's Why Exelixis (EXEL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Smartest Biotech Stocks to Buy With $50
One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share prices, it's possible to buy shares of quality stocks with $50 -- or less.
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
Biotech leader Exelixis stock is attempting to regain a recent buy point during Monday's stock market rally. The post Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally appeared first on Investor's Business Daily.
Exelixis Growth Continues with Big Money Boosts
Oncology company Exelixis, Inc. (EXEL) growing business, eyeing more.
